What question did this study set out to answer?

To evaluate the pharmacokinetics of ribociclib across different ethnicities in breast cancer patients.

April 10, 2026Open Access

Comprehensive Ethnicity Assessment of Ribociclib Pharmacokinetics in Patients With Early and Advanced Breast Cancer

Key Points

To evaluate the pharmacokinetics of ribociclib across different ethnicities in breast cancer patients.
Conducted a pharmacokinetic analysis comparing Asian and non-Asian patients.
Reviewed dose recommendations for ribociclib in different ethnic groups.
Ribociclib pharmacokinetics were comparable between Asian and non-Asian patients.
Current dosing recommendations for Asian patients are supported by the findings.

Abstract

This comprehensive ethnicity assessment suggests comparable PK of ribociclib between Asian and non-Asian patients and supports current dose recommendations in Asian patients.

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Yan Ji

F. Sun

M. Sato

Journals

Clinical Therapeutics

Actions

Institutions

Novartis (Switzerland)

National Taiwan University Hospital

Novartis (China)

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Comprehensive Ethnicity Assessment of Ribociclib Pharmacokinetics in Patients With Early and Advanced Breast Cancer

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study

Also consider

Also consider